Agents and Actions

, Volume 4, Issue 4, pp 264–270 | Cite as

The pharmacology of azatadine, a potential antiallergy drug

  • Salvatore Tozzi
  • Franklin E. Roth
  • Irving I. A. Tabachnick
Research Reports

Abstract

Azatadine (6–11-dihydro-11-[1-methyl-4-piperclylidene]-5H{5,6}cyclohepta{1,2-b}pyridine maleate {1∶2}), a nitrogen analog of cyproheptadine has been studied for its antiallergy properties. It was compared in vivo and in vitro to cyproheptadine and seven (7) standard antihistamines: chlorpheniramine, promethazine, diphenhydramine, phenindamine, chloropyriline, tripelennamine and chlorcylizine; an antiserotonin, methysergide; and an anticholinergic, atropine.

Azatadine possesses potent antihistaminic, anticholinergic, antiserotinin and antianaphylactic properties. In vitro, azatadine's antihistamine potency is equal to chlorpheniramine, cyproheptadine, phenindamine, chloropyrilene and greater than the rest of the antihistamines studied. Its anticholinergic potency is 1/3 that of atropine, equal to promethazine and cyproheptadine and greater than the rest of the antihistamines studied. Its antiserotonin potency is 1/4 that of methysergide, equal to promethazine and greater than the rest of antihistamines studied.

In vivo, azatadine's ability to protect guinea-pigs from histamine lethality (i.v.) and histamine-induced dyspnea is greater than all of the antihistamines studied. Its ability to protect guinea-pigs from acetylcholine-induced dyspnea is equal to atropine and greater than all of the antihistamines studied. Its ability to protect guinea-pigs from serotonin-induced dyspnea is 1/6 that of cyproheptadine, 1/8 that of methysergide and greater than all of the antihistamines studied.

Azatadine is a more potent antianaphylactic agent and has greater therapeutic indices than cyproheptadine in both mice and guinea-pigs.

Keywords

Nitrogen Pyridine Histamine Atropine Therapeutic Index 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    F. Magnus, Pflugers Arch. Ges. Physiol.102, 123 (1904).CrossRefGoogle Scholar
  2. [2]
    D.J. Finney,Probit Analysis (Cambridge Press 1964).Google Scholar
  3. [3]
    E.J. Ariens,Affinity and Intrinsic Activity in the Theory of competitive Inhibition. I. Problems and Theory, Arch. Int. Pharmacodyn.99, 32 (1954).PubMedGoogle Scholar
  4. [4]
    J. M. Van Rossum andVan den Brink,Cumulative Dose-Response Curves, Arch. Int. Pharmacodyn.143/ 1–2, 240–246 (1963).PubMedGoogle Scholar
  5. [5]
    W.W. Fleming, I.S. de la Fande Westfall andL.B. Jellett,Log Normal Distribution of Equi-Effective Doses of Norepinephrine and Acetylcholine in Several Tissues. J. Pharmac. exp. Ther.181/2, 339 (1972).Google Scholar
  6. [6]
    P. Amblard,Essais d'un nouvel antihistaminique en dermatologie, Lyon Méditerranée Med.50, 57–58, 61–62 (1969).Google Scholar
  7. [7]
    A. Sabbah,Etude clinique et pharmacologique d'un nouvel antihistaminique, le dimaleate d'azatadine dans les maladies par hypersensibilité, Vie méd.41, 5401–5403 (1969).Google Scholar
  8. [8]
    G. Dumon, et al,Essais cliniques d'une préparation antitussive le Sch 10.649, Marseille méd.106, 989–992 (1969).Google Scholar
  9. [9]
    P. Chavanis,Action tussiplegique d'un nouvel antihistaminique de synthèse au cours de manifestations de sensibilisation des voies respiratoires de l'adulte et de l'enfant, Cah. méd. Lyonnais146, 1492, 1495–1496 (1970).Google Scholar
  10. [10]
    B. Sigal et al,Action antiprurigineuse de dimaleate d'azatadine dans certaines affections dermatologiques. Gaz. méd. France77, 364–365 (1970).Google Scholar
  11. [11]
    F. Crepin,Essai thérapeutique — l'emploi de l'idulian dans les rhinites congestives mixtes et spasmodiques, Ann. méd. Reims8, 233–235 (1971).Google Scholar
  12. [12]
    M.L. Texier,Expérimentation clinique de l'indulian en dermatologie, Bordeaux méd.3, 937–938 (March 1971).Google Scholar
  13. [13]
    J.-P. Grilliat et al,Action antihistaminique de l'indulian étudiée sur l'histamino-libération cutanée par 48/80, Ann. méd. Nancy11, 721–724 (1972).Google Scholar

Copyright information

© Birkhäuser Verlag 1974

Authors and Affiliations

  • Salvatore Tozzi
    • 1
  • Franklin E. Roth
    • 1
  • Irving I. A. Tabachnick
    • 1
  1. 1.Department of PharmacologySchering CorporationBloomfieldUSA

Personalised recommendations